Friday, August 28, 2026
FDA approves Pfizer-BioNTech's XFG-adapted COVID vaccine
The FDA approved the Pfizer-BioNTech COVID-19 vaccine reformulated to target the XFG variant for the 2026-2027 season on August 27, covering adults 65 and older and people ages 5-64 with at least one underlying condition that puts them at high risk for severe disease. The approval follows the European Commission's July 29 authorization of the same XFG-adapted formulation, and shipping to the US began immediately.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.